INCYTE CORP 8-K

What Happened

• On June 8, 2026 Incyte Corporation announced it has entered into a definitive agreement to acquire Vega Therapeutics, Inc., which is a wholly owned subsidiary of Star Therapeutics, LLC. The announcement was made via a press release attached to the Form 8-K (Exhibit 99.1). The current 8-K was filed under Item 8.01 (Other Events).

Key Details

• Transaction announced: Incyte to acquire Vega Therapeutics, Inc.
• Date filed: June 8, 2026 (Form 8-K).
• Target ownership: Vega is a wholly owned subsidiary of Star Therapeutics, LLC.
• Filing disclosure: Press release attached as Exhibit 99.1; no purchase price or transaction financial terms were disclosed in this 8-K.

Why It Matters

• This acquisition is a strategic corporate development that may affect Incyte’s product pipeline, R&D focus, and future revenue potential. Because the 8-K does not disclose financial terms, investors should watch for follow-up SEC filings or company releases that provide purchase price, deal structure, integration plans, and any expected timing or regulatory approvals.